Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

LEUKOCARE Licenses Biomarker Cell-Free DNA to Trillium Diagnostics

Published: Wednesday, October 10, 2012
Last Updated: Wednesday, October 10, 2012
Bookmark and Share
Trillium to develop a commercial IVD assay kit for early diagnosis of infection/sepsis.

LEUKOCARE AG and Trillium Diagnostics, LLC have announced that both partners have formed a strategic alliance regarding the development and marketing of LEUKOCARE’s patented method for the detection of inflammatory activity using the novel biomarker circulating cell-free DNA (cf-DNA).

Trillium will use the technology to develop a commercial assay for the diagnosis of sepsis.

Neutrophil-derived DNA is the major component of cf-DNA, which has recently been recognized as an important predictive biomarker in severely ill patients with acute or chronic inflammatory disorders.

LEUKOCARE has granted to Trillium an exclusive, royalty-bearing license of its patent and know-how for the method of measuring the quantity of cf-DNA to develop a commercial IVD assay kit for the worldwide market.

Trillium intends to establish a cf-DNA test as a simple and cost effective tool for healthcare professionals to obtain clinically informative data on patients with suspected infection/sepsis.

The development process is expected to return an approved and marketable assay in about 2 years’ time.

"A prognostic assay for sepsis will represent a tremendous improvement in intensive care medicine," said Bruce Davis, M.D., CEO and President of Trillium Diagnostics.

Davis continued, "It clearly would fulfil an unmet medical need to help identify sepsis patients at early stage and to initiate rapid treatment actions."

Dr Davis added, “cf-DNA is an important addition to our patented infection/sepsis diagnostic assays of neutrophil CD64 expression (Leuko64 assay) and soluble CD163 (Macro163 assay). We hope these three assays used in parallel will provide unparalleled sensitivity and specificity in diagnosis.”

Michael Scholl, CEO of LEUKOCARE, said: “We have found a strong and competent partner in Trillium. Its pertinent expertise in developing and marketing diagnostic assays will make the best use of the potential of the cf-DNA biomarker. LEUKOCARE will participate in the future success of the product by significant royalties.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
CDC Updates Zika Recommendations
CDC has issued updated Zika recommendations and guidance for healthcare providers with a focus on sexual transmission.
Review of the Analysis of Haemoglobin A1c for Diabetes Diagnostics
This paper aims to clarify methods, units, quality requirements, reference and cutoff limits for hemoglobin A1c (HbA1c) and ratio of blood glucose/HbA1c on the basis of the results from Finnish quality control surveys by comparing them to the literature.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
72% Rise in Metastatic Prostate Cancer
Over the 2003-2013 period metastatic cancer has increased by an average of 72%, this could be caused by lax screening, more aggressive disease or both.
Lab-Tested Diagnosis Needed When Treating Persistent Diarrhea
New PCR multiplex method makes lab testing more effective.
Biomarker for Multiple Sclerosis Detection Discovered
Winthrop-University Hospital researchers discover biomarker for multiple sclerosis detection.
Scientists Link Bipolar Disorder to Unexpected Brain Region
Researchers from The Scripps Research Institute have found that gene within the brain’s striatum could be linked to biopolar disorder.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!